Velegraki Maria, Stiff Andrew, Papadaki Helen A, Li Zihai
Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center-James, Columbus, OH 43210, USA.
Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.
J Clin Med. 2022 Aug 21;11(16):4908. doi: 10.3390/jcm11164908.
Myelodysplastic syndromes (MDS) are hematopoietic malignancies characterized by the clonal expansion of hematopoietic stem cells, bone marrow failure manifested by cytopenias, and increased risk for evolving to acute myeloid leukemia. Despite the fact that the acquisition of somatic mutations is considered key for the initiation of the disease, the bone marrow microenvironment also plays significant roles in MDS by providing the right niche and even shaping the malignant clone. Aberrant immune responses are frequent in MDS and are implicated in many aspects of MDS pathogenesis. Recently, myeloid-derived suppressor cells (MDSCs) have gained attention for their possible implication in the immune dysregulation associated with MDS. Here, we summarize the key findings regarding the expansion of MDSCs in MDS, their role in MDS pathogenesis and immune dysregulation, as well their potential as a new therapeutic target for MDS.
骨髓增生异常综合征（MDS）是造血系统恶性肿瘤，其特征为造血干细胞的克隆性扩增、血细胞减少所表现出的骨髓衰竭，以及向急性髓系白血病转化的风险增加。尽管体细胞突变的获得被认为是该疾病起始的关键，但骨髓微环境通过提供合适的生态位甚至塑造恶性克隆，在MDS中也发挥着重要作用。异常免疫反应在MDS中很常见，并与MDS发病机制的许多方面有关。最近，髓系来源的抑制性细胞（MDSC）因其可能与MDS相关的免疫失调有关而受到关注。在此，我们总结了关于MDS中MDSC扩增、它们在MDS发病机制和免疫失调中的作用，以及它们作为MDS新治疗靶点的潜力的关键发现。
